|530.48||+2.99||+0.57%||Vol 535.63K||1Y Perf -10.40%|
|Jun 16th, 2021 13:23 DELAYED|
|2.36 0.45%||- -|
|Target Price||622.21||Analyst Rating||Moderate Buy 1.95|
|Potential %||17.13||Finscreener Ranking||★★★★+ 58.53|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 59.55|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 77.19|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||56.52B||Earnings Rating||Neutral|
|Price Range Ratio 52W %||40.01||Earnings Date||4th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Aug 2021|
|Estimated EPS Next Report||16.53|
|EPS Growth Next 5 Years %||18.30|
|Avg. Weekly Volume||621.13K|
|Avg. Monthly Volume||677.62K|
|Avg. Quarterly Volume||817.12K|
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock closed at 527.49 per share at the end of the most recent trading day (a -0.24% change compared to the prior day closing price) with a volume of 547.48K shares and market capitalization of 56.52B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9123 people. Regeneron Pharmaceuticals Inc. CEO is Leonard S. Schleifer.
The one-year performance of Regeneron Pharmaceuticals Inc. stock is -10.4%, while year-to-date (YTD) performance is 9.19%. REGN stock has a five-year performance of 43.92%. Its 52-week range is between 441 and 664.64, which gives REGN stock a 52-week price range ratio of 40.01%
Regeneron Pharmaceuticals Inc. currently has a PE ratio of 14.90, a price-to-book (PB) ratio of 4.68, a price-to-sale (PS) ratio of 6.02, a price to cashflow ratio of 23.10, a PEG ratio of 2.32, a ROA of 23.19%, a ROC of 28.78% and a ROE of 32.18%. The company’s profit margin is 43.64%, its EBITDA margin is 51.20%, and its revenue ttm is $9.20 Billion , which makes it $87.87 revenue per share.
Of the last four earnings reports from Regeneron Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $16.53 for the next earnings report. Regeneron Pharmaceuticals Inc.’s next earnings report date is 04th Aug 2021.
The consensus rating of Wall Street analysts for Regeneron Pharmaceuticals Inc. is Moderate Buy (1.95), with a target price of $622.21, which is +17.13% compared to the current price. The earnings rating for Regeneron Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Regeneron Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Regeneron Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 9.24, ATR14 : 11.76, CCI20 : 130.01, Chaikin Money Flow : 0.02, MACD : 7.55, Money Flow Index : 63.11, ROC : 6.49, RSI : 62.27, STOCH (14,3) : 85.97, STOCH RSI : 0.66, UO : 60.74, Williams %R : -14.03), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Regeneron Pharmaceuticals Inc. in the last 12-months were: Andrew J Murphy (Option Excercise at a value of $1 018 850), Andrew J Murphy (Sold 20 937 shares of value $12 584 164 ), Arthur Frederick Ryan (Sold 709 shares of value $402 861 ), Bonnie L. Bassler (Option Excercise at a value of $1 002 923), Bonnie L. Bassler (Sold 2 559 shares of value $1 612 210 ), Christine A. Poon (Option Excercise at a value of $1 137 550), Christine A. Poon (Sold 40 000 shares of value $24 048 714 ), Christopher R. Fenimore (Option Excercise at a value of $1 907 015), Christopher R. Fenimore (Sold 7 265 shares of value $4 482 532 ), Daniel P. Van Plew (Option Excercise at a value of $13 434 750), Daniel P. Van Plew (Sold 27 109 shares of value $16 560 737 ), George D. Yancopoulos (Option Excercise at a value of $20 712 050), George L. Sing (Option Excercise at a value of $7 514 542), George L. Sing (Sold 126 050 shares of value $77 406 199 ), Huda Y. Zoghbi (Option Excercise at a value of $1 337 231), Huda Y. Zoghbi (Sold 3 412 shares of value $2 217 800 ), Joseph J. Larosa (Option Excercise at a value of $520 300), Joseph J. Larosa (Sold 4 672 shares of value $2 873 467 ), Joseph L. Goldstein (Option Excercise at a value of $11 756 755), Joseph L. Goldstein (Sold 28 716 shares of value $16 271 124 ), Marion McCourt (Option Excercise at a value of $1 714 650), Marion McCourt (Sold 5 000 shares of value $2 819 430 ), Michael S. Brown (Option Excercise at a value of $5 859 395), Michael S. Brown (Sold 14 596 shares of value $8 393 778 ), N. Anthony Coles (Option Excercise at a value of $3 800), Neil Stahl (Option Excercise at a value of $7 815 575), Neil Stahl (Sold 17 521 shares of value $9 101 459 ), P. Roy Vagelos (Option Excercise at a value of $13 007 500), P. Roy Vagelos (Sold 100 380 shares of value $60 523 056 ), Robert E. Landry (Option Excercise at a value of $16 877 453), Robert E. Landry (Sold 3 656 shares of value $2 338 080 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.